<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03708393</url>
  </required_header>
  <id_info>
    <org_study_id>Reader-01</org_study_id>
    <nct_id>NCT03708393</nct_id>
  </id_info>
  <brief_title>Imagio Feasibility Multi-Reader, Multi-Case Study</brief_title>
  <official_title>Imagio Feasibility Multi-Reader, Multi-Case Study of Optoacoustic Images Versus Imagio Ultrasound to Guide Decision to Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seno Medical Instruments Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Radiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seno Medical Instruments Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled, blinded, multi-reader, multi-case study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Imagio Feasibility Reader Study-01 Study is intended to evaluate if a subsequent pivotal&#xD;
      study can be implemented to test prospective hypotheses for pre-specified effectiveness&#xD;
      endpoints with an acceptable sample size. The Feasibility Study will be based on ITD masses&#xD;
      from the PIONEER (NCT01943916) Pivotal study to simultaneously reflect the distributions with&#xD;
      and without mammograms as well as site CDU BI-RADS scores within benign and malignant masses&#xD;
      as strata. The study population will be split into 3 cohorts - Cohort 1, the 120 patient ITD&#xD;
      Population used to run the primary/ secondary analyses. Cohort 2, 30 patients used to run&#xD;
      exploratory analyses on false negative rate and Cohort 3, 5 patients used to run exploratory&#xD;
      analyses on specific mass types&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Actual">December 9, 2018</completion_date>
  <primary_completion_date type="Actual">December 9, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This will be a controlled, blinded, multi-reader, multi-case (MRMC) study using a sequential design. The study will include 5-12 independent readers depending on qualifications and availability.&#xD;
Imagio (IUS+OA) Training to be completed prior to any reads taking place. Read 1 is immediately followed by Read 2 within the same read session.&#xD;
Read 1 (Control): Mammogram (if available) + History + IUS (stills and videos provided), IUS Probability of Malignancy (POM) and BI-RADS scored and the data form locked.&#xD;
Read 2 (Test): Mammogram (if available) + History + IUS (stills and videos provided), and Imagio (IUS+OA) (stills and videos provided). An interim IUS POM and BI-RADS is recorded as well as a combined Imagio (IUS+OA) POM and BIRADS Pre and Post SenoGram on separate data forms.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Independent Readers blinded to mass diagnosis</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The Gain in Imagio IUS Alone Specificity vs Imagio (IUS+OA) Specificity at Fixed 95-99% Sensitivity (fSp), Cohort 1</measure>
    <time_frame>Baseline to 12 month follow-up</time_frame>
    <description>Primary effectiveness endpoint was the specificity of Imagio [IUS+OA] compared to IUS alone at fixed 95-99% sensitivity (fSp) interpolated from the area under the curve (AUC) of receiver operating characteristic (ROC) curves, averaged across all 10 independent readers. Both imaging modalities (IUS alone and IUS+OA) were read for each subject (subject as own control). Results for each imaging modality compared to biopsy diagnosis or 12-month follow-up ruling of benign as determined by truth panel (ground truth).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial Receiver Operating Characteristic (ROC) Area Under the Curve (pAUC), Cohort 1</measure>
    <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months (≥11 months)</time_frame>
    <description>pAUC considers only the region of the ROC space that corresponds to clinically relevant values of sensitivity defined as 95% to 99% for Imagio [IUS+OA] vs. IUS alone; averaged across 10 readers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BiRads [Breast Imaging Reporting and Data System] Downgrades and Upgrades- Cohort 1</measure>
    <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months</time_frame>
    <description>The cumulative effect of downgrades and upgrades for benign masses expressed as the net gain of True Negative reads</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Negative Likelihood Ratio (NLR) for IUS vs. Imagio® (IUS+OA), Cohort 1</measure>
    <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months (≥11 months)</time_frame>
    <description>NLR (Imagio [IUS+OA] vs. IUS alone); averaged across 10 readers (all readers).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SenoGram Usage Cohort 1 for Imagio (IUS+OA) Only</measure>
    <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months</time_frame>
    <description>SenoGram Utilization by number of readers using the SenoGram reported by the readers. SenoGram is not used for Imagio IUS Arm only Imagio (IUS+OA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SenoGram Performance</measure>
    <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months</time_frame>
    <description>Sensitivity of SenoGram estimated from cross-validation - Cohort 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SenoGram Performance</measure>
    <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months</time_frame>
    <description>Specificity of SenoGram estimated from cross-validation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Imagio IUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Read 1 - Mammo (as available) + Imagio Ultrasound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imagio (IUS+OA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Imagio (IUS+OA)</intervention_name>
    <description>The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study</description>
    <arm_group_label>Imagio (IUS+OA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Imagio Ultrasound</intervention_name>
    <description>Imagio ultrasound images to be reviewed as part of the reader study</description>
    <arm_group_label>Imagio IUS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mammography</intervention_name>
    <description>Mammography images as available per standard of care</description>
    <arm_group_label>Imagio (IUS+OA)</arm_group_label>
    <arm_group_label>Imagio IUS</arm_group_label>
    <other_name>Mammo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Female subjects participating in the PIONEER-0 Study of the Imagio Breast Imaging System&#xD;
        with known clinical status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Female subjects who did not have known clinical status in the PIONEER-0 Study of the&#xD;
        Imagio Breast Imaging System with known clinical status&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Thomas Stavros, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seno Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American College of Radiology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <results_first_submitted>April 19, 2021</results_first_submitted>
  <results_first_submitted_qc>July 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2021</results_first_posted>
  <disposition_first_submitted>April 1, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>July 14, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 6, 2021</disposition_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03708393/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03708393/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>New Independent Reader Feasibility Study (new readers re-reading a sub-set of randomly selected images acquired during PIONEER-01 Study (NCT01943916); Reader-01 study execution dates: 13 Nov 2018 to 6 Dec 2018</recruitment_details>
      <pre_assignment_details>Breast mass images were acquired during PIONEER-01 study. The Reader-01 study-single arm, sequentially read (IUS vs. Imagio [IUS+OA]), controlled, blinded, multi-reader, multi-case (MRMC) feasibility study. New readers recruited; NO new subjects were recruited. Subject baseline, demographic and safety data comes from PIONEER-01 subjects who were randomly selected for Reader-01 study. Outcome measures compared IUS vs. IUS+OA. Truth based on biopsy diagnosis or 12 Mo F/U truth panel decision.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall (Subjects Randomly Selected From PIONEER-01 Study)</title>
          <description>Each subject in all 3 cohorts had one mass that was read by all readers. Each subject served as her own control, with imaging of each mass by both IUS and IUS+OA modalities. All subjects for all 3 cohorts were included in safety analysis. All subjects for all 3 cohorts were followed and completed in the same manner. Cohort 1 (n=120 was representative of the subject population for the primary analysis, Cohort 2 (n=30) was special population for internal study of FN's and Cohort 3 (n=5) was for internal study of DCIS masses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-diagnose (ITD)</population>
      <group_list>
        <group group_id="B1">
          <title>Overall (Subjects Randomly Selected From PIONEER-01 Study)</title>
          <description>Each subject had one mass that was read by all readers. Each subject served as her own control, with imaging of each mass by both IUS and IUS+OA modalities. Therefore, baseline data are for overall population only.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mass Diagnosis</title>
          <description>Mass diagnosis by (biopsy result or Truth Panel decision = TPB) TPB was determined as ground truth obtained during the PIONEER-01 Study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subjects: Benign (includes benign + Truth Panel Benign [TPB]) (Cohort 1)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects: Malignant (Cohort 1)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects: Malignant false negative in PIONEER-01 (Cohort 2)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects: Malignant atypical (Cohort 3)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Gain in Imagio IUS Alone Specificity vs Imagio (IUS+OA) Specificity at Fixed 95-99% Sensitivity (fSp), Cohort 1</title>
        <description>Primary effectiveness endpoint was the specificity of Imagio [IUS+OA] compared to IUS alone at fixed 95-99% sensitivity (fSp) interpolated from the area under the curve (AUC) of receiver operating characteristic (ROC) curves, averaged across all 10 independent readers. Both imaging modalities (IUS alone and IUS+OA) were read for each subject (subject as own control). Results for each imaging modality compared to biopsy diagnosis or 12-month follow-up ruling of benign as determined by truth panel (ground truth).</description>
        <time_frame>Baseline to 12 month follow-up</time_frame>
        <population>120 patients/masses were included in Cohort 1-the Intent-to-diagnose (ITD) population used to run the analysis to set the sample size for the future pivotal Reader-02 Study, 30 masses Cohort 2 to assess False negative rate, and 5 Cohort 3 DCIS, lymphoma, etc. masses to assess how readers scored. 155 masses in total across all cohorts analyzed for the Safety population analysis</population>
        <group_list>
          <group group_id="O1">
            <title>IUS Alone</title>
            <description>IUS alone imaging</description>
          </group>
          <group group_id="O2">
            <title>Imagio (IUS+OA)</title>
            <description>IUS+OA imaging</description>
          </group>
        </group_list>
        <measure>
          <title>The Gain in Imagio IUS Alone Specificity vs Imagio (IUS+OA) Specificity at Fixed 95-99% Sensitivity (fSp), Cohort 1</title>
          <description>Primary effectiveness endpoint was the specificity of Imagio [IUS+OA] compared to IUS alone at fixed 95-99% sensitivity (fSp) interpolated from the area under the curve (AUC) of receiver operating characteristic (ROC) curves, averaged across all 10 independent readers. Both imaging modalities (IUS alone and IUS+OA) were read for each subject (subject as own control). Results for each imaging modality compared to biopsy diagnosis or 12-month follow-up ruling of benign as determined by truth panel (ground truth).</description>
          <population>120 patients/masses were included in Cohort 1-the Intent-to-diagnose (ITD) population used to run the analysis to set the sample size for the future pivotal Reader-02 Study, 30 masses Cohort 2 to assess False negative rate, and 5 Cohort 3 DCIS, lymphoma, etc. masses to assess how readers scored. 155 masses in total across all cohorts analyzed for the Safety population analysis</population>
          <units>Percent of correct benign masses</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fSp (95.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9" lower_limit="69.1" upper_limit="92.7"/>
                    <measurement group_id="O2" value="75.4" lower_limit="61.5" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fSp (96.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" lower_limit="65.7" upper_limit="91.7"/>
                    <measurement group_id="O2" value="71.4" lower_limit="55.8" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fSp (97.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" lower_limit="61.4" upper_limit="90.3"/>
                    <measurement group_id="O2" value="66.1" lower_limit="48.6" upper_limit="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fSp (97.5%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="58.7" upper_limit="89.4"/>
                    <measurement group_id="O2" value="62.8" lower_limit="44.1" upper_limit="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fSp (98.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" lower_limit="55.4" upper_limit="88.3"/>
                    <measurement group_id="O2" value="58.9" lower_limit="38.8" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fSp (99.0%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" lower_limit="45.8" upper_limit="84.6"/>
                    <measurement group_id="O2" value="47.7" lower_limit="24.5" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Receiver Operating Characteristic (ROC) Area Under the Curve (pAUC), Cohort 1</title>
        <description>pAUC considers only the region of the ROC space that corresponds to clinically relevant values of sensitivity defined as 95% to 99% for Imagio [IUS+OA] vs. IUS alone; averaged across 10 readers.</description>
        <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months (≥11 months)</time_frame>
        <population>Cohort 1, pAUC considers only the region of the ROC space that corresponds to clinically relevant values of sensitivity defined as 95% to 99% for Imagio [IUS+OA] vs. IUS alone; averaged across 10 readers.</population>
        <group_list>
          <group group_id="O1">
            <title>Imagio IUS</title>
            <description>Read 1 - Mammo (as available) + Imagio Ultrasound&#xD;
Imagio Ultrasound: Imagio ultrasound images to be reviewed as part of the reader study&#xD;
Mammography: Mammography images as available per standard of care</description>
          </group>
          <group group_id="O2">
            <title>Imagio (IUS+OA)</title>
            <description>Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)&#xD;
Imagio (IUS+OA): The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study&#xD;
Mammography: Mammography images as available per standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Receiver Operating Characteristic (ROC) Area Under the Curve (pAUC), Cohort 1</title>
          <description>pAUC considers only the region of the ROC space that corresponds to clinically relevant values of sensitivity defined as 95% to 99% for Imagio [IUS+OA] vs. IUS alone; averaged across 10 readers.</description>
          <population>Cohort 1, pAUC considers only the region of the ROC space that corresponds to clinically relevant values of sensitivity defined as 95% to 99% for Imagio [IUS+OA] vs. IUS alone; averaged across 10 readers.</population>
          <units>Probability as percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.9" upper_limit="3.3"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.4" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BiRads [Breast Imaging Reporting and Data System] Downgrades and Upgrades- Cohort 1</title>
        <description>The cumulative effect of downgrades and upgrades for benign masses expressed as the net gain of True Negative reads</description>
        <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months</time_frame>
        <population>ITD Population- Number of Subjects/Masses 120</population>
        <group_list>
          <group group_id="O1">
            <title>Imagio IUS</title>
            <description>Read 1 - Mammo (as available) + Imagio Ultrasound&#xD;
Imagio Ultrasound: Imagio ultrasound images to be reviewed as part of the reader study&#xD;
Mammography: Mammography images as available per standard of care</description>
          </group>
          <group group_id="O2">
            <title>Imagio (IUS+OA)</title>
            <description>Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)&#xD;
Imagio (IUS+OA): The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study&#xD;
Mammography: Mammography images as available per standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>BiRads [Breast Imaging Reporting and Data System] Downgrades and Upgrades- Cohort 1</title>
          <description>The cumulative effect of downgrades and upgrades for benign masses expressed as the net gain of True Negative reads</description>
          <population>ITD Population- Number of Subjects/Masses 120</population>
          <units>% of correctly identified benign masses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Negative Likelihood Ratio (NLR) for IUS vs. Imagio® (IUS+OA), Cohort 1</title>
        <description>NLR (Imagio [IUS+OA] vs. IUS alone); averaged across 10 readers (all readers).</description>
        <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months (≥11 months)</time_frame>
        <population>Cohort 1 - 120</population>
        <group_list>
          <group group_id="O1">
            <title>IUS Alone</title>
            <description>Results for IUS alone readings</description>
          </group>
          <group group_id="O2">
            <title>Imagio (IUS+OA)</title>
            <description>IUS+OA imaging&#xD;
Results for Imagio readings</description>
          </group>
        </group_list>
        <measure>
          <title>The Negative Likelihood Ratio (NLR) for IUS vs. Imagio® (IUS+OA), Cohort 1</title>
          <description>NLR (Imagio [IUS+OA] vs. IUS alone); averaged across 10 readers (all readers).</description>
          <population>Cohort 1 - 120</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>99% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".049" lower_limit=".04" upper_limit=".07"/>
                    <measurement group_id="O2" value=".094" lower_limit=".08" upper_limit=".11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SenoGram Usage Cohort 1 for Imagio (IUS+OA) Only</title>
        <description>SenoGram Utilization by number of readers using the SenoGram reported by the readers. SenoGram is not used for Imagio IUS Arm only Imagio (IUS+OA)</description>
        <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months</time_frame>
        <population>Cohort 1</population>
        <group_list>
          <group group_id="O1">
            <title>Imagio IUS</title>
            <description>Read 1 - Mammo (as available) + Imagio Ultrasound&#xD;
Imagio Ultrasound: Imagio ultrasound images to be reviewed as part of the reader study&#xD;
Mammography: Mammography images as available per standard of care</description>
          </group>
          <group group_id="O2">
            <title>Imagio (IUS+OA)</title>
            <description>Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)&#xD;
Imagio (IUS+OA): The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study&#xD;
Mammography: Mammography images as available per standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>SenoGram Usage Cohort 1 for Imagio (IUS+OA) Only</title>
          <description>SenoGram Utilization by number of readers using the SenoGram reported by the readers. SenoGram is not used for Imagio IUS Arm only Imagio (IUS+OA)</description>
          <population>Cohort 1</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">SenoGram is not used for Imagio IUS Arm only Imagio (IUS+OA)</measurement>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SenoGram Performance</title>
        <description>Sensitivity of SenoGram estimated from cross-validation - Cohort 1</description>
        <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months</time_frame>
        <population>ITD Population</population>
        <group_list>
          <group group_id="O1">
            <title>Imagio IUS</title>
            <description>Read 1 - Mammo (as available) + Imagio Ultrasound&#xD;
Imagio Ultrasound: Imagio ultrasound images to be reviewed as part of the reader study&#xD;
Mammography: Mammography images as available per standard of care</description>
          </group>
          <group group_id="O2">
            <title>Imagio (IUS+OA)</title>
            <description>Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)&#xD;
Imagio (IUS+OA): The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study&#xD;
Mammography: Mammography images as available per standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>SenoGram Performance</title>
          <description>Sensitivity of SenoGram estimated from cross-validation - Cohort 1</description>
          <population>ITD Population</population>
          <units>Percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">SenoGram not used for IUS Arm</measurement>
                    <measurement group_id="O2" value="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SenoGram Performance</title>
        <description>Specificity of SenoGram estimated from cross-validation</description>
        <time_frame>Imagio [IUS+OA] and IUS readings relative to biopsy results and TRUTH PANEL review of NDU cases with follow-up at 12 months</time_frame>
        <population>ITD Population - Cohort 1</population>
        <group_list>
          <group group_id="O1">
            <title>IUS Alone</title>
            <description>Results for IUS alone readings</description>
          </group>
          <group group_id="O2">
            <title>Imagio (IUS+OA)</title>
            <description>IUS+OA imaging&#xD;
Results for Imagio readings</description>
          </group>
        </group_list>
        <measure>
          <title>SenoGram Performance</title>
          <description>Specificity of SenoGram estimated from cross-validation</description>
          <population>ITD Population - Cohort 1</population>
          <units>Percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">SenoGram not used for IUS Arm</measurement>
                    <measurement group_id="O2" value="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 12 months +/- 30 days follow-up. Adverse Events were recorded from the use of the Imagio during the original PIONEER Study and reported out for those participants/masses selected for the Reader-01 Independent Reader Study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Overall (Masses Randomly Selected From PIONEER-01 Study)</title>
          <description>Each subject had one mass that was read by all readers. Each subject served as her own control, with imaging of each mass by both IUS and IUS+OA modalities. Therefore, safety data are for overall population only.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shaan Schaeffer VP of Clinical Operations</name_or_title>
      <organization>Seno Medical</organization>
      <phone>610-698-3259</phone>
      <email>sschaeffer@senomedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

